Literature DB >> 15880955

Salivary gland cancer in Finland 1991--96: an evaluation of 237 cases.

Heikki Luukkaa1, Pekka Klemi, Ilmo Leivo, Petri Koivunen, Jussi Laranne, Antti Mäkitie, Jukka Virtaniemi, Susanna Hinkka, Reidar Grénman.   

Abstract

CONCLUSION: In this material consisting of various salivary gland carcinomas, stage I, male gender and age were the most powerful predictors of patient outcome.
OBJECTIVES: To retrieve the records of all salivary gland cancer (SGC) patients diagnosed in Finland between 1991 and 1996 and to evaluate the incidence, histological type and location of SGC, the treatment given and the outcome.
MATERIAL AND METHODS: The records for all SGCs (n =286) diagnosed in Finland between 1991 and 1996 and reported to the Finnish Cancer Registry were retrieved. The histological re-evaluation and retrospective study involved 237 SGC patients.
RESULTS: The study population consisted of 125 males and 112 females. The mean age was 59 years (males 61 years, females 58 years). Follow-up was at least 5 years. The commonest tumor location was the parotid gland (n = 152; 64%), followed by the minor salivary glands (n =46; 19%), the submandibular gland (n =38; 16%) and the sublingual gland (n = 1; 0.4%). The most frequent histological types of SGC were adenoid cystic carcinoma (n =65; 27%), mucoepidermoid carcinoma (n =45; 19%) and acinic cell carcinoma (n =41; 17%). Surgery, either alone or in combination with other treatment modalities, was used in 209 cases (88%). Radiotherapy was given to 136 patients (57%), 13 of whom (5%) did not undergo surgery. The 5-year overall survival rate was 56.5%, and for stages I-IV it was 78%, 25%, 21% and 23%, respectively (p <0.001; log-rank test). Of the commonest tumor types, the best 5-year relative survival rate was for patients with acinic cell carcinoma (96%), followed by those with mucoepidermoid (79%) and adenoid cystic carcinoma (74%).

Entities:  

Mesh:

Year:  2005        PMID: 15880955     DOI: 10.1080/00016480510003174

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  30 in total

1.  Pattern of recurrent disease in major salivary gland adenocystic carcinoma.

Authors:  Karoliina Hirvonen; Leif Bäck; Kauko Saarilahti; Ilmo Leivo; Jaana Hagström; Antti A Mäkitie
Journal:  Virchows Arch       Date:  2015-04-03       Impact factor: 4.064

2.  Expression pattern of claudins 1 and 3-an auxiliary tool in predicting behavior of mucoepidermoid carcinoma of salivary gland origin.

Authors:  Katri Aro; Luiz Eduardo Blumer Rosa; Ibrahim O Bello; Ylermi Soini; Antti A Mäkitie; Tuula Salo; Ilmo Leivo
Journal:  Virchows Arch       Date:  2010-12-24       Impact factor: 4.064

3.  Management and outcome of salivary duct carcinoma in major salivary glands.

Authors:  Elina Salovaara; Olli Hakala; Leif Bäck; Petri Koivunen; Kauko Saarilahti; Fabricio Passador-Santos; Ilmo Leivo; Antti A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-03-22       Impact factor: 2.503

4.  Diagnostic role of DOG1 and p63 immunohistochemistry in salivary gland carcinomas.

Authors:  Nermine M Abd Raboh; Sarah A Hakim
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Parotid carcinoma: Current diagnostic workup and treatment.

Authors:  Vincent L M Vander Poorten; Francis Marchal; Sandra Nuyts; Paul M J Clement
Journal:  Indian J Surg Oncol       Date:  2010-11-21

Review 6.  Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved.

Authors:  Markus Stenner; J Peter Klussmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-04       Impact factor: 2.503

7.  Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States.

Authors:  Houda Boukheris; Rochelle E Curtis; Charles E Land; Graça M Dores
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

8.  A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.

Authors:  Mark R Gilbert; Arun Sharma; Nicole C Schmitt; Jonas T Johnson; Robert L Ferris; Umamaheswar Duvvuri; Seungwon Kim
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-05-01       Impact factor: 6.223

Review 9.  Salivary gland cancer stem cells.

Authors:  April Adams; Kristy Warner; Jacques E Nör
Journal:  Oral Oncol       Date:  2013-06-28       Impact factor: 5.337

10.  Primary and non-primary parotid malignancies: comparison of treatment modalities and outcomes.

Authors:  Sylvain Morinière; Sophie Périé; Jean Lacau St Guily
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-05-30       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.